Cargando…
Cardiovascular Toxicity of Novel HER2-Targeted Therapies in the Treatment of Breast Cancer
PURPOSE OF REVIEW: HER2-targeted therapies have led to improved clinical outcomes in early and advanced breast cancer (BC). We review the long-term cardiotoxicity of HER2-targeted therapy in early and advanced BC, our current knowledge of cardiotoxicity of novel HER2-targeted therapies, and propose...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8395382/ https://www.ncbi.nlm.nih.gov/pubmed/34453232 http://dx.doi.org/10.1007/s11912-021-01114-x |
_version_ | 1783744158820728832 |
---|---|
author | Dent, Susan F. Morse, Amber Burnette, Sarah Guha, Avirup Moore, Heather |
author_facet | Dent, Susan F. Morse, Amber Burnette, Sarah Guha, Avirup Moore, Heather |
author_sort | Dent, Susan F. |
collection | PubMed |
description | PURPOSE OF REVIEW: HER2-targeted therapies have led to improved clinical outcomes in early and advanced breast cancer (BC). We review the long-term cardiotoxicity of HER2-targeted therapy in early and advanced BC, our current knowledge of cardiotoxicity of novel HER2-targeted therapies, and propose a cardiac monitoring (CM) strategy for this population. RECENT FINDINGS: Long-term data from studies with HER2-targeted therapy in the adjuvant setting have failed to demonstrate an increase in cardiotoxicity over time, and rates of cardiotoxicity seen with novel HER2 agents remain low. Despite over a decade of experience with HER2-targeted therapy, CM in clinical practice is inconsistent in patients with early BC and almost non-existent in advanced BC. SUMMARY: Long-term follow-up of clinical trials with HER2-targeted agents in early and advanced BC has failed to demonstrate increased rates of cardiotoxicity over time, attesting to the long-term safety of this class of drugs for the majority of patients, although the long-term cardiac safety of newer HER2 agents in the non-clinical trial setting is largely unknown. We propose CM incorporating clinical history, cardiac imaging, and biomarkers. |
format | Online Article Text |
id | pubmed-8395382 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-83953822021-08-27 Cardiovascular Toxicity of Novel HER2-Targeted Therapies in the Treatment of Breast Cancer Dent, Susan F. Morse, Amber Burnette, Sarah Guha, Avirup Moore, Heather Curr Oncol Rep Cardio-oncology (EH Yang, Section Editor) PURPOSE OF REVIEW: HER2-targeted therapies have led to improved clinical outcomes in early and advanced breast cancer (BC). We review the long-term cardiotoxicity of HER2-targeted therapy in early and advanced BC, our current knowledge of cardiotoxicity of novel HER2-targeted therapies, and propose a cardiac monitoring (CM) strategy for this population. RECENT FINDINGS: Long-term data from studies with HER2-targeted therapy in the adjuvant setting have failed to demonstrate an increase in cardiotoxicity over time, and rates of cardiotoxicity seen with novel HER2 agents remain low. Despite over a decade of experience with HER2-targeted therapy, CM in clinical practice is inconsistent in patients with early BC and almost non-existent in advanced BC. SUMMARY: Long-term follow-up of clinical trials with HER2-targeted agents in early and advanced BC has failed to demonstrate increased rates of cardiotoxicity over time, attesting to the long-term safety of this class of drugs for the majority of patients, although the long-term cardiac safety of newer HER2 agents in the non-clinical trial setting is largely unknown. We propose CM incorporating clinical history, cardiac imaging, and biomarkers. Springer US 2021-08-27 2021 /pmc/articles/PMC8395382/ /pubmed/34453232 http://dx.doi.org/10.1007/s11912-021-01114-x Text en © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Cardio-oncology (EH Yang, Section Editor) Dent, Susan F. Morse, Amber Burnette, Sarah Guha, Avirup Moore, Heather Cardiovascular Toxicity of Novel HER2-Targeted Therapies in the Treatment of Breast Cancer |
title | Cardiovascular Toxicity of Novel HER2-Targeted Therapies in the Treatment of Breast Cancer |
title_full | Cardiovascular Toxicity of Novel HER2-Targeted Therapies in the Treatment of Breast Cancer |
title_fullStr | Cardiovascular Toxicity of Novel HER2-Targeted Therapies in the Treatment of Breast Cancer |
title_full_unstemmed | Cardiovascular Toxicity of Novel HER2-Targeted Therapies in the Treatment of Breast Cancer |
title_short | Cardiovascular Toxicity of Novel HER2-Targeted Therapies in the Treatment of Breast Cancer |
title_sort | cardiovascular toxicity of novel her2-targeted therapies in the treatment of breast cancer |
topic | Cardio-oncology (EH Yang, Section Editor) |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8395382/ https://www.ncbi.nlm.nih.gov/pubmed/34453232 http://dx.doi.org/10.1007/s11912-021-01114-x |
work_keys_str_mv | AT dentsusanf cardiovasculartoxicityofnovelher2targetedtherapiesinthetreatmentofbreastcancer AT morseamber cardiovasculartoxicityofnovelher2targetedtherapiesinthetreatmentofbreastcancer AT burnettesarah cardiovasculartoxicityofnovelher2targetedtherapiesinthetreatmentofbreastcancer AT guhaavirup cardiovasculartoxicityofnovelher2targetedtherapiesinthetreatmentofbreastcancer AT mooreheather cardiovasculartoxicityofnovelher2targetedtherapiesinthetreatmentofbreastcancer |